SPX3,756.71-26.57 -0.70%
DIA300.13-2.66 -0.88%
IXIC11,112.82-35.81 -0.32%

Pfizer Begins Dosing in Phase 3 Study of mRNA-Based Influenza Vaccine

Pfizer Begins Dosing in Phase 3 Study of mRNA-Based Influenza Vaccine

MT Newswires · 09/14/2022 03:25

Please log in to view news